Breaking Drug News: Combination GLP-1s, Treatment for Kids, and Lp(a)

What do new drug reports really mean for your treatment?

Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.

KEY TAKEAWAYS

• Understanding the difference between efficacy estimand and treatment policy estimand.

• Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.

• Semaglutide's effectiveness in children and its implications.

NOTABLE QUOTE

"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper

LINKS & RESOURCES

Learn more about Diabesity Foundations: learn.diabesityinstitute.org

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.